Johnson & Johnson asked rival COVID-19 vaccine makers to probe clotting risks - WSJ
From Reuters employees
(Reuters) - Johnson & Johnson had turned to competition from COVID-19 vaccine manufacturers to jointly investigate the risks of blood clots, the Wall Street Journal reported Friday, citing people familiar with the matter.
AstraZeneca, plagued by similar blood clotting concerns for weeks, agreed, while Pfizer Inc and Moderna Executive declined, saying their vaccines are safe, the report said. (https://on.wsj.com/2Q7E4Ho)
U.S. federal health officials on Tuesday recommended that Johnson & Johnson's vaccine be discontinued for at least a few days after six women under the age of 50 developed rare blood clots after receiving the shot.
Last week, European regulators said they were screening for rare blood clots in four recipients of the J&J shot in the US. After that, according to the WSJ report, the company began reaching out to other vaccine manufacturers.
Pfizer and Moderna also objected because they did not see the need to redouble the efforts of agencies and companies already looking for and investigating the cause of blood clots, the report said.
The specific adverse event was not reported by those who received the Pfizer and Moderna vaccines, the companies said.
J&J, AstraZeneca, Pfizer, and Moderna were not immediately available to comment on the report.
You should check here to buy the best price guaranteed products.
Erdogan calls on Pope to keep denouncing Gaza violence
Crypto Liquidations Top $2.4 Billion in 24 Hours
American households will finally get their Child Tax Credit boost — here’s when that first payment will arrive
A Republican congressman who denied there was an insurrection and likened Capitol rioters to 'tourists' was photographed barricading the chamber doors against them
Woman accused of killing her 2 kids with meat cleaver after argument with husband
Ricky Schroder confronts Costco employee over mask requirement in viral video: 'You're just going to listen to their rules?'